Literature DB >> 10583263

Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.

F Ravandi1, J Cortes, M Albitar, R Arlinghaus, J Qiang Guo, M Talpaz, H M Kantarjian.   

Abstract

We investigated the significance of p185BCR/ABL expression in patients with chronic myelogenous leukaemia (CML) in relation to disease features, therapy and outcome. Results of Western blot analysis for 1384 patients referred with a diagnosis of CML to our institution from 1989 to 1997 were reviewed. Clinical characteristics, results of cytogenetic analysis and RT-PCR for BCR rearrangement were analysed. Five patients with Ph-positive CML expressing the p185BCR/ABL hybrid protein were identified. By RT-PCR, bone marrow specimens of these patients were confirmed to have an e1a2 junction. The median age at diagnosis of these patients was 55 years (range 43-76). All had elevated white cell counts at diagnosis (median 50 x 109/l, range 11.7-163 x 109/l). Four patients had monocytosis (range 10-16%) with a low neutrophil/monocyte ratio in the peripheral blood (range 3.4-5.7). Patients presented with various stages of the disease (two in chronic-phase CP, two in accelerated-phase AP, and one in blastic-phase BP). The clinical course and therapy of the patients varied, with one patient receiving hydroxyurea only, three patients receiving hydroxyurea followed by interferon-alpha based regimens and bone marrow transplantation. The patient presenting in BP was treated with combination chemotherapy. The clinical outcome of the patients was also varied with one patient alive and in complete remission (with complete cytogenetic remission after transplant) and four patients dead after progression to more advanced stages. We conclude that patients with Ph-positive p185BCR/ABL CML frequently present with monocytosis and a low neutrophil/monocyte ratio in the peripheral blood, aiding the speculation that the presence of the p185BCR/ABL hybrid protein may contribute to a phenotype intermediate between CML and CMML. Of interest, the only other specific clinical feature identified was the absence of splenomegaly in four of five patients. There was no definite association with transformation to lymphoid blast phase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583263     DOI: 10.1046/j.1365-2141.1999.01736.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

2.  BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.

Authors:  Dan Jones; Rajyalakshmi Luthra; Jorge Cortes; Deborah Thomas; Susan O'Brien; Carlos Bueso-Ramos; Seema Hai; Farhad Ravandi; Marcos de Lima; Hagop Kantarjian; Jeffrey L Jorgensen
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

Review 3.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

Review 4.  Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies.

Authors:  Falko Fend; Oliver Bock; Markus Kremer; Katja Specht; Leticia Quintanilla-Martinez
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

5.  A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.

Authors:  Natini Jinawath; Alexis Norris-Kirby; B Douglas Smith; Christopher D Gocke; Denise A Batista; Constance A Griffin; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2009-06-04       Impact factor: 5.568

6.  Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.

Authors:  Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2009-06-16       Impact factor: 22.113

7.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard Stone; Ilene Galinsky; Edward Fox; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

8.  Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

Authors:  Ellen Weisberg; Laurie Catley; Renee D Wright; Daisy Moreno; Lolita Banerji; Arghya Ray; Paul W Manley; Juergen Mestan; Doriano Fabbro; Jingrui Jiang; Elizabeth Hall-Meyers; Linda Callahan; Jamie L DellaGatta; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

9.  Childhood chronic myeloid leukemia with monocytosis.

Authors:  Nidhi Gupta; Ritu Gupta; Surender Kumar Sharawat; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2010-09-30       Impact factor: 5.319

10.  p210BCR-ABL1- Chronic myeloid leukemia presents with monocytosis.

Authors:  Xiaofei Wang; Fei Wang; Zie Wang; Yuantang Li; Devin Wang; Huanling Wu; Bingchang Zhang
Journal:  Clin Case Rep       Date:  2020-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.